Report cover image

Global Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 199 Pages
SKU # APRC20552593

Description

Summary

According to APO Research, The global Biosimilars market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Biosimilars include Teva Pharmaceutical, Samsung Biologics, Novartis, Merck KgaA, Mylan, Roche, Eli Lilly, Pfizer and Gan & Lee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biosimilars sales, projected growth trends, production technology, application and end-user industry.

Biosimilars Segment by Company

Teva Pharmaceutical
Samsung Biologics
Novartis
Merck KgaA
Mylan
Roche
Eli Lilly
Pfizer
Gan & Lee Pharmaceuticals
Biogen
Amgen
Stada Arzneimittel AG
Probiomed
JCR Pharmaceuticals
Gedeon Richter
Fresenius Kabi AG
Dr. Reddy's Laboratories
Coherus Bioscience
Chong Kun Dang
Celltrion
Boehringer Ingelheim
Biocon
Biocad
Apotex
Biosimilars Segment by Type

Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
Biosimilars Segment by Application

Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Others
Biosimilars Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Biosimilars Market Size, 2020 VS 2024 VS 2031
1.3 Global Biosimilars Market Size Estimates and Forecasts (2020-2031)
1.4 Global Biosimilars Sales Estimates and Forecasts (2020-2031)
1.5 Global Biosimilars Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Biosimilars Market Dynamics
2.1 Biosimilars Industry Trends
2.2 Biosimilars Industry Drivers
2.3 Biosimilars Industry Opportunities and Challenges
2.4 Biosimilars Industry Restraints
3 Biosimilars Market by Manufacturers
3.1 Global Biosimilars Revenue by Manufacturers (2020-2025)
3.2 Global Biosimilars Sales by Manufacturers (2020-2025)
3.3 Global Biosimilars Average Sales Price by Manufacturers (2020-2025)
3.4 Global Biosimilars Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Biosimilars Manufacturers, Product Type & Application
3.7 Global Biosimilars Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Biosimilars Market CR5 and HHI
3.8.2 Global Top 5 and 10 Biosimilars Players Market Share by Revenue in 2024
3.8.3 2024 Biosimilars Tier 1, Tier 2, and Tier 3
4 Biosimilars Market by Type
4.1 Biosimilars Type Introduction
4.1.1 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
4.1.2 Recombinant Glycosylated Proteins
4.2 Global Biosimilars Sales by Type
4.2.1 Global Biosimilars Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Biosimilars Sales by Type (2020-2031)
4.2.3 Global Biosimilars Sales Market Share by Type (2020-2031)
4.3 Global Biosimilars Revenue by Type
4.3.1 Global Biosimilars Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Biosimilars Revenue by Type (2020-2031)
4.3.3 Global Biosimilars Revenue Market Share by Type (2020-2031)
5 Biosimilars Market by Application
5.1 Biosimilars Application Introduction
5.1.1 Oncology
5.1.2 Blood Disorders
5.1.3 Growth Hormonal Deficiency
5.1.4 Chronic and Autoimmune Disorders
5.1.5 Others
5.2 Global Biosimilars Sales by Application
5.2.1 Global Biosimilars Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Biosimilars Sales by Application (2020-2031)
5.2.3 Global Biosimilars Sales Market Share by Application (2020-2031)
5.3 Global Biosimilars Revenue by Application
5.3.1 Global Biosimilars Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Biosimilars Revenue by Application (2020-2031)
5.3.3 Global Biosimilars Revenue Market Share by Application (2020-2031)
6 Global Biosimilars Sales by Region
6.1 Global Biosimilars Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Biosimilars Sales by Region (2020-2031)
6.2.1 Global Biosimilars Sales by Region (2020-2025)
6.2.2 Global Biosimilars Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Biosimilars Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Biosimilars Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Biosimilars Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Biosimilars Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Biosimilars Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Biosimilars Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Biosimilars Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Biosimilars Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Biosimilars Revenue by Region
7.1 Global Biosimilars Revenue by Region
7.1.1 Global Biosimilars Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Biosimilars Revenue by Region (2020-2025)
7.1.3 Global Biosimilars Revenue by Region (2026-2031)
7.1.4 Global Biosimilars Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Biosimilars Revenue (2020-2031)
7.2.2 North America Biosimilars Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Biosimilars Revenue (2020-2031)
7.3.2 Europe Biosimilars Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Biosimilars Revenue (2020-2031)
7.4.2 Asia-Pacific Biosimilars Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Biosimilars Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Biosimilars Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Teva Pharmaceutical
8.1.1 Teva Pharmaceutical Comapny Information
8.1.2 Teva Pharmaceutical Business Overview
8.1.3 Teva Pharmaceutical Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Teva Pharmaceutical Biosimilars Product Portfolio
8.1.5 Teva Pharmaceutical Recent Developments
8.2 Samsung Biologics
8.2.1 Samsung Biologics Comapny Information
8.2.2 Samsung Biologics Business Overview
8.2.3 Samsung Biologics Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Samsung Biologics Biosimilars Product Portfolio
8.2.5 Samsung Biologics Recent Developments
8.3 Novartis
8.3.1 Novartis Comapny Information
8.3.2 Novartis Business Overview
8.3.3 Novartis Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Novartis Biosimilars Product Portfolio
8.3.5 Novartis Recent Developments
8.4 Merck KgaA
8.4.1 Merck KgaA Comapny Information
8.4.2 Merck KgaA Business Overview
8.4.3 Merck KgaA Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Merck KgaA Biosimilars Product Portfolio
8.4.5 Merck KgaA Recent Developments
8.5 Mylan
8.5.1 Mylan Comapny Information
8.5.2 Mylan Business Overview
8.5.3 Mylan Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Mylan Biosimilars Product Portfolio
8.5.5 Mylan Recent Developments
8.6 Roche
8.6.1 Roche Comapny Information
8.6.2 Roche Business Overview
8.6.3 Roche Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Roche Biosimilars Product Portfolio
8.6.5 Roche Recent Developments
8.7 Eli Lilly
8.7.1 Eli Lilly Comapny Information
8.7.2 Eli Lilly Business Overview
8.7.3 Eli Lilly Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Eli Lilly Biosimilars Product Portfolio
8.7.5 Eli Lilly Recent Developments
8.8 Pfizer
8.8.1 Pfizer Comapny Information
8.8.2 Pfizer Business Overview
8.8.3 Pfizer Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Pfizer Biosimilars Product Portfolio
8.8.5 Pfizer Recent Developments
8.9 Gan & Lee Pharmaceuticals
8.9.1 Gan & Lee Pharmaceuticals Comapny Information
8.9.2 Gan & Lee Pharmaceuticals Business Overview
8.9.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
8.9.5 Gan & Lee Pharmaceuticals Recent Developments
8.10 Biogen
8.10.1 Biogen Comapny Information
8.10.2 Biogen Business Overview
8.10.3 Biogen Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Biogen Biosimilars Product Portfolio
8.10.5 Biogen Recent Developments
8.11 Amgen
8.11.1 Amgen Comapny Information
8.11.2 Amgen Business Overview
8.11.3 Amgen Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Amgen Biosimilars Product Portfolio
8.11.5 Amgen Recent Developments
8.12 Stada Arzneimittel AG
8.12.1 Stada Arzneimittel AG Comapny Information
8.12.2 Stada Arzneimittel AG Business Overview
8.12.3 Stada Arzneimittel AG Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Stada Arzneimittel AG Biosimilars Product Portfolio
8.12.5 Stada Arzneimittel AG Recent Developments
8.13 Probiomed
8.13.1 Probiomed Comapny Information
8.13.2 Probiomed Business Overview
8.13.3 Probiomed Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Probiomed Biosimilars Product Portfolio
8.13.5 Probiomed Recent Developments
8.14 JCR Pharmaceuticals
8.14.1 JCR Pharmaceuticals Comapny Information
8.14.2 JCR Pharmaceuticals Business Overview
8.14.3 JCR Pharmaceuticals Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 JCR Pharmaceuticals Biosimilars Product Portfolio
8.14.5 JCR Pharmaceuticals Recent Developments
8.15 Gedeon Richter
8.15.1 Gedeon Richter Comapny Information
8.15.2 Gedeon Richter Business Overview
8.15.3 Gedeon Richter Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 Gedeon Richter Biosimilars Product Portfolio
8.15.5 Gedeon Richter Recent Developments
8.16 Fresenius Kabi AG
8.16.1 Fresenius Kabi AG Comapny Information
8.16.2 Fresenius Kabi AG Business Overview
8.16.3 Fresenius Kabi AG Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.16.4 Fresenius Kabi AG Biosimilars Product Portfolio
8.16.5 Fresenius Kabi AG Recent Developments
8.17 Dr. Reddy's Laboratories
8.17.1 Dr. Reddy's Laboratories Comapny Information
8.17.2 Dr. Reddy's Laboratories Business Overview
8.17.3 Dr. Reddy's Laboratories Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.17.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
8.17.5 Dr. Reddy's Laboratories Recent Developments
8.18 Coherus Bioscience
8.18.1 Coherus Bioscience Comapny Information
8.18.2 Coherus Bioscience Business Overview
8.18.3 Coherus Bioscience Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.18.4 Coherus Bioscience Biosimilars Product Portfolio
8.18.5 Coherus Bioscience Recent Developments
8.19 Chong Kun Dang
8.19.1 Chong Kun Dang Comapny Information
8.19.2 Chong Kun Dang Business Overview
8.19.3 Chong Kun Dang Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.19.4 Chong Kun Dang Biosimilars Product Portfolio
8.19.5 Chong Kun Dang Recent Developments
8.20 Celltrion
8.20.1 Celltrion Comapny Information
8.20.2 Celltrion Business Overview
8.20.3 Celltrion Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.20.4 Celltrion Biosimilars Product Portfolio
8.20.5 Celltrion Recent Developments
8.21 Boehringer Ingelheim
8.21.1 Boehringer Ingelheim Comapny Information
8.21.2 Boehringer Ingelheim Business Overview
8.21.3 Boehringer Ingelheim Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.21.4 Boehringer Ingelheim Biosimilars Product Portfolio
8.21.5 Boehringer Ingelheim Recent Developments
8.22 Biocon
8.22.1 Biocon Comapny Information
8.22.2 Biocon Business Overview
8.22.3 Biocon Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.22.4 Biocon Biosimilars Product Portfolio
8.22.5 Biocon Recent Developments
8.23 Biocad
8.23.1 Biocad Comapny Information
8.23.2 Biocad Business Overview
8.23.3 Biocad Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.23.4 Biocad Biosimilars Product Portfolio
8.23.5 Biocad Recent Developments
8.24 Apotex
8.24.1 Apotex Comapny Information
8.24.2 Apotex Business Overview
8.24.3 Apotex Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
8.24.4 Apotex Biosimilars Product Portfolio
8.24.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Biosimilars Value Chain Analysis
9.1.1 Biosimilars Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Biosimilars Production Mode & Process
9.2 Biosimilars Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Biosimilars Distributors
9.2.3 Biosimilars Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.